secwatch.observer — SEC 8-K summary
======================================

Issuer:     TELA Bio, Inc. (TELA)
CIK:        0001561921
Form:       8-K
Filed at:   2024-03-20T23:59:59+00:00
Accession:  0001104659-24-036394
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TELA Bio sells NIVIS distribution rights to MiMedx for at least $8M, up to $12M
-------------------------------------------------------------------------------

- Initial $5.0M payment; future payments min $3.0M, max $7.0M based on NIVIS net sales over two years.
- Total consideration at least $8M and up to $12M from MiMedx for the wound care product.
- NIVIS is an absorbent collagen matrix indicated for wound management and minor bleeding.
- TELA to focus on hernia repair and reconstructive surgery products, including new LIQUIFIX and OviTex configurations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1561921/000110465924036394/0001104659-24-036394-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1561921/000110465924036394/tm249144d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-036394

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer